Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Merck & Co.'s Zepatier receives marketing authorization in Europe

Aug. 1, 2016

Phase II ECOSPOR study of microbiome therapeutic SER-109 fails to meet primary endpoint

Aug. 1, 2016

University of Cape Town researchers identify new antimalarial candidate

Aug. 1, 2016

University of Illinois discloses antifungal compounds

July 29, 2016

FIOCRUZ patents antituberculosis agents

July 29, 2016

International partnership to tackle the threat posed by antimicrobial resistance

July 29, 2016

DPP Zika IgM/IgG assay obtains CE mark for rapid point-of-care detection of Zika virus

July 28, 2016

Phase I study of FluGen's universal influenza vaccine begins

July 28, 2016

Burnet Institute and ARTES Biotechnology to jointly develop HCV vaccine

July 28, 2016

Pneumococcal vaccination using novel hybrid biological-biomaterial vector

July 28, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...